ExploRNA Therapeutics, in collaboration with Takara Bio, has published a comprehensive technical note detailing an optimized co-transcriptional mRNA synthesis workflow that combines ExploRNA’s tetranucleotide Cap1 analog, AvantCap® Q1, with Takara Bio’s engineered PrimeCap™ T7 RNA Polymerase.
Achieving efficient, clinical-grade mRNA production requires balancing high capping efficiency and transcription yields while suppressing immunogenic double-stranded RNA (dsRNA) byproducts. The newly released evaluation demonstrates how pairing these two advanced reagents delivers superior synthesis performance across critical manufacturing metrics:
-
High and Consistent Transcription Yield: Maximizing mRNA output per reaction volume.
-
Up to 99% Co-Transcriptional Capping Efficiency: Ensuring robust translational potency without requiring complex post-transcriptional enzymatic steps.
-
Significantly Reduced dsRNA Formation: Minimizing unwanted cellular immune activation compared to standard wild-type T7 polymerases.
-
Resource Optimization: Achieving maximum capping fidelity while lowering the overall input requirement of cap analog.
Whether you are developing next-generation mRNA therapeutics or optimizing routine in vitro transcription (IVT) protocols, this workflow offers a direct route to higher purity and improved batch consistency.
The full technical note—including experimental parameters, comparative gel data, and capping quantification—is now available for download.
